Published in Lancet on February 23, 2008
Top Down Versus Step Up Strategies in Crohn's Disease | NCT00554710
Reduce Risk for Crohn's Disease Patients (RCT) | NCT02852694
Care Path for the Management of Ulcerative Colitis (CONSTRUCT) | NCT01882426
The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives | NCT03291743
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol (2014) 1.80
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest (2011) 1.47
Crohn's disease complicated by strictures: a systematic review. Gut (2013) 1.46
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol (2015) 1.44
Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. Arthritis Rheumatol (2016) 1.38
Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol (2009) 1.25
Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.15
Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol (2012) 1.15
The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol (2010) 1.12
Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol (2010) 1.09
How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol (2010) 1.09
The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int (2009) 1.07
Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease. Am J Gastroenterol (2015) 1.07
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol (2009) 1.06
Long-term clinical outcomes of korean patient with Crohn's disease following early use of infliximab. Intest Res (2014) 1.05
State-of-the-art medical prevention of postoperative recurrence of Crohn's disease. Nat Rev Gastroenterol Hepatol (2013) 1.03
Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol (2014) 1.02
Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol (2013) 1.01
Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.99
Caught in the Akt: regulation of Wnt signaling in the intestine. Gastroenterology (2010) 0.99
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis (2011) 0.99
Medical management of Crohn's disease. BMJ (2008) 0.97
Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol (2008) 0.96
Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap Adv Gastroenterol (2009) 0.96
Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol (2010) 0.94
Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol (2010) 0.93
Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol (2010) 0.92
Use of the Crohn's disease activity index in clinical trials of biological agents. World J Gastroenterol (2008) 0.92
Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol (2012) 0.91
Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol (2011) 0.91
Use of thiopurines in inflammatory bowel disease. World J Gastroenterol (2013) 0.89
Efficacy of early treatment with infliximab in pediatric Crohn's disease. World J Gastroenterol (2010) 0.89
New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) (2014) 0.89
Postoperative Crohn's disease recurrence: a practical approach. World J Gastroenterol (2008) 0.88
The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. Clin Gastroenterol Hepatol (2014) 0.88
MRI in Crohn's disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol (2011) 0.88
Optimal use of biologics in the management of Crohn's disease. Therap Adv Gastroenterol (2010) 0.87
Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion (2009) 0.87
Mucosal healing and deep remission: what does it mean? World J Gastroenterol (2013) 0.87
SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. J Crohns Colitis (2014) 0.86
Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol (2009) 0.86
Current and future role of biomarkers in Crohn's disease risk assessment and treatment. Clin Exp Gastroenterol (2011) 0.86
Surgery for Crohn's disease in the era of biologicals: a reduced need or delayed verdict? World J Gastroenterol (2012) 0.86
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.85
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol (2013) 0.85
Infliximab extends the duration until the first surgery in patients with Crohn's disease. Biomed Res Int (2013) 0.85
Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection. Clin Exp Immunol (2014) 0.83
A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr (2010) 0.83
Randomized controlled trial: moxibustion and acupuncture for the treatment of Crohn's disease. World J Gastroenterol (2014) 0.83
Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. World J Gastroenterol (2013) 0.82
Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling. PLoS One (2013) 0.82
NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy. Dig Dis Sci (2011) 0.82
National trends in intestinal resection for Crohn's disease in the post-biologic era. Int J Colorectal Dis (2013) 0.81
How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis (2013) 0.81
Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Bamboo joint-like appearance of the stomach: a stable endoscopic landmark for Crohn's disease regardless of anti-tumor necrosis factor alpha treatment. Med Sci Monit (2014) 0.81
Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci (2010) 0.81
Low-dose azathioprine effectively improves mucosal healing in Chinese patients with small bowel Crohn's disease. J Dig Dis (2014) 0.81
Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics (2009) 0.81
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol (2010) 0.81
Interleukin 34: a new modulator of human and experimental inflammatory bowel disease. Clin Sci (Lond) (2015) 0.81
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
Monitoring Crohn's disease during anti-TNF-α therapy: validation of the magnetic resonance enterography global score (MEGS) against a combined clinical reference standard. Eur Radiol (2015) 0.81
Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Aliment Pharmacol Ther (2016) 0.80
Oral Manifestations of Crohn's Disease: A Case Report and Review of the Literature. Case Rep Dent (2015) 0.80
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol (2015) 0.80
Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. World J Gastroenterol (2014) 0.80
Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol (2011) 0.80
Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2014) 0.80
Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.80
How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort. Int J Colorectal Dis (2014) 0.79
Stem cells: HSCT for Crohn's disease: work in progress or a bridge too far? Nat Rev Gastroenterol Hepatol (2016) 0.79
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol (2016) 0.79
Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients. Dig Dis Sci (2016) 0.79
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis (2011) 0.79
Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ (2012) 0.79
Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol (2010) 0.79
Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis. J Biol Chem (2014) 0.79
Making therapeutic decisions in inflammatory bowel disease: the role of patients. Curr Opin Gastroenterol (2009) 0.79
Clinical predictors of thiopurine-related adverse events in Crohn's disease. World J Gastroenterol (2015) 0.78
Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease. BMC Gastroenterol (2014) 0.78
Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. Ther Adv Chronic Dis (2015) 0.78
Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn's disease. BMC Gastroenterol (2014) 0.78
Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery. Dig Dis Sci (2016) 0.78
Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn's Disease Patients: Results from the CONNECT Study. PLoS One (2015) 0.78
Role of conventional therapies in the era of biological treatment in Crohn's disease. World J Gastroenterol (2011) 0.78
Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol (2011) 0.78
Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm (2015) 0.78
Optimizing post-operative Crohn's disease treatment. Ann Gastroenterol (2014) 0.78
Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol (2011) 0.78
Initial combination therapy in early Crohn's disease. Lancet (2008) 0.78
Conflicting results on the efficacy of enteral nutrition during infliximab maintenance therapy for Crohn's disease are correct. Dig Dis Sci (2013) 0.78
Human Embryonic Stem Cell Therapy in Crohn's Disease: A Case Report. Am J Case Rep (2016) 0.78
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med (2008) 7.79
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Caesarean delivery rates and pregnancy outcomes: the 2005 WHO global survey on maternal and perinatal health in Latin America. Lancet (2006) 6.56
Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Maternal and neonatal individual risks and benefits associated with caesarean delivery: multicentre prospective study. BMJ (2007) 4.92
A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med (2009) 4.84
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed. J Clin Epidemiol (2010) 4.50
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet (2009) 3.97
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol (2006) 3.72
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension (2009) 3.48
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol (2004) 3.25
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol (2004) 2.99
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol (2002) 2.94
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis (2013) 2.82
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2012) 2.80
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet (2008) 2.67
Mandatory second opinion to reduce rates of unnecessary caesarean sections in Latin America: a cluster randomised controlled trial. Lancet (2004) 2.59
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut (2011) 2.58
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis (2012) 2.55
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53
Ethical issues posed by cluster randomized trials in health research. Trials (2011) 2.43
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology (2003) 2.37
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis (2009) 2.33
Butyricicoccus pullicaecorum in inflammatory bowel disease. Gut (2012) 2.32
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31